FDG-PET and MRI in the Evolution of New-Onset Refractory Status Epilepticus

References

1. 1.↵
   2. Gaspard N,
   3. Foreman BP,
   4. Alvarez V, et al

   ; Critical Care EEG Monitoring Research Consortium (CCEMRC). New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology 2015;85:1604–13 doi:10.1212/WNL.0000000000001940 pmid:26296517

   CrossRefPubMed
2. 2.↵
   2. Hirsch LJ,
   3. Gaspard N,
   4. van Baalen A, et al

   . Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 2018;59:739–44 doi:10.1111/epi.14016 pmid:29399791

   CrossRefPubMed
3. 3.↵
   2. Graus F,
   3. Titulaer MJ,
   4. Balu R, et al

   . A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391–404 doi:10.1016/S1474-4422(15)00401-9 pmid:26906964

   CrossRefPubMed
4. 4.↵
   2. Ismail FY,
   3. Kossoff EH

   . AERRPS, DESC, NORSE, FIRES: Multi-labeling or distinct epileptic entities? Epilepsia 2011;52:e185–89 doi:10.1111/j.1528-1167.2011.03293.x pmid:22004046

   CrossRefPubMed
5. 5.↵
   2. Sakuma H,
   3. Awaya Y,
   4. Shiomi M, et al

   . Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis. Acta Neurol Scand 2010;121:251–56 doi:10.1111/j.1600-0404.2009.01198.x pmid:20028339

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Costello DJ,
   3. Kilbride RD,
   4. Cole AJ

   . Cryptogenic new onset refractory status epilepticus (NORSE) in adults: infectious or not? J Neurol Sci 2009;277:26–31 doi:10.1016/j.jns.2008.10.007 pmid:19013586

   CrossRefPubMed
7. 7.↵
   2. Byun J,
   3. Lee S,
   4. Jung K, et al

   . Effect of immunotherapy on seizure outcome in patients with autoimmune encephalitis: a prospective observational registry study. PLoS One 2016;11:e0146455 doi:10.1371/journal.pone.0146455 pmid:26771547

   CrossRefPubMed
8. 8.↵
   2. Gall CR,
   3. Jumma O,
   4. Mohanraj R

   . Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy. Seizure 2013;22:217–20 doi:10.1016/j.seizure.2012.12.016 pmid:23333762

   CrossRefPubMed
9. 9.↵
   2. Iizuka T,
   3. Kanazawa N,
   4. Kaneko J, et al

   . Cryptogenic NORSE: its distinctive clinical features and response to immunotherapy. Neurol Neuroimmunol Neuroinflamm 2017;4:e396 doi:10.1212/NXI.0000000000000396 pmid:28959704

   Abstract/FREE Full Text
10. 10.↵
    2. Khawaja AM,
    3. DeWolfe JL,
    4. Miller DW, et al

    . New-onset refractory status epilepticus (NORSE): the potential role for immunotherapy. Epilepsy Behav 2015;47:17–23 doi:10.1016/j.yebeh.2015.04.054 pmid:26010959

    CrossRefPubMed
11. 11.↵
    2. Li J,
    3. Saldivar C,
    4. Maganti RK

    . Plasma exchange in cryptogenic new onset refractory status epilepticus. Seizure 2013;22:70–73 doi:10.1016/j.seizure.2012.09.011 pmid:23068971

    CrossRefPubMed
12. 12.↵
    2. Kenney-Jung DL,
    3. Vezzani A,
    4. Kahoud RJ, et al

    . Febrile infection-related epilepsy syndrome treated with anakinra. Ann Neurol 2016;80:939–45 doi:10.1002/ana.24806 pmid:27770579

    CrossRefPubMed
13. 13.↵
    2. Leypoldt F,
    3. Buchert R,
    4. Kleiter I, et al

    . Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry 2012;83:681–86 doi:10.1136/jnnp-2011-301969 pmid:22566598

    Abstract/FREE Full Text
14. 14.↵
    2. Titulaer M,
    3. Soffietti R,
    4. Dalmau J, et al

    ; European Federation of Neurological Societies. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18:19-e3 doi:10.1111/j.1468-1331.2010.03220.x pmid:20880069

    CrossRefPubMed
15. 15.↵
    2. Cole AJ

    . Status epilepticus and periictal imaging. Epilepsia 2004;45:72–77 pmid:15281962

    CrossRefPubMed
16. 16.↵
    2. Kim S,
    3. Mountz JM

    . SPECT imaging of epilepsy: an overview and comparison with F-18 FDG PET. Int J Mol Imaging 2011;2011:813028 doi:10.1155/2011/813028 pmid:21785722

    CrossRefPubMed
17. 17.↵
    2. Sarria-Estrada S,
    3. Toledo M,
    4. Lorenzo-Bosquet C, et al

    . Neuroimaging in status epilepticus secondary to paraneoplastic autoimmune encephalitis. Clin Radiol 2014;69:795–803 doi:10.1016/j.crad.2014.03.012 pmid:24824979

    CrossRefPubMed
18. 18.↵
    2. Baumgartner A,
    3. Rauer S,
    4. Mader I, et al

    . Cerebral FDG PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol 2013;260:2744–53 doi:10.1007/s00415-013-7048-2 pmid:23900756

    CrossRefPubMed
19. 19.↵
    2. Probasco JC,
    3. Solnes L,
    4. Nalluri A, et al

    . Abnormal brain metabolism on FDG PET/CT is a common early finding in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 2017;4:e352 doi:10.1212/NXI.0000000000000352 pmid:28567435

    CrossRefPubMed
20. 20.↵
    2. Finke C,
    3. Prüss H,
    4. Heine J, et al

    . Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol 2017;74:50–59 doi:10.1001/jamaneurol.2016.4226 pmid:27893017

    CrossRefPubMed
21. 21.↵
    2. Heine J,
    3. Prüss H,
    4. Bartsch T, et al

    . Imaging of autoimmune encephalitis–relevance for clinical practice and hippocampal function. Neuroscience 2015;309:68–83 doi:10.1016/j.neuroscience.2015.05.037 pmid:26012492

    CrossRefPubMed
22. 22.↵
    2. Miller TD,
    3. Chong TT,
    4. Aimola Davies AM, et al

    . Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain 2017;140:1212–19 doi:10.1093/brain/awx070 pmid:28369215

    CrossRefPubMed
23. 23.↵
    2. Wagner J,
    3. Schoene-Bake J,
    4. Malter MP, et al

    . Quantitative FLAIR analysis indicates predominant affection of the amygdala in antibody-associated limbic encephalitis. Epilepsia 2013;54:1679–87 doi:10.1111/epi.12320 pmid:23889589

    CrossRefPubMed
24. 24.↵
    2. Khan NL,
    3. Jeffree MA,
    4. Good C, et al

    . Histopathology of VGKC antibody-associated limbic encephalitis. Neurology 2009;72:1703–05 doi:10.1212/WNL.0b013e3181a55eb3 pmid:19433746

    FREE Full Text
25. 25.↵
    2. Vincent A,
    3. Bien CG,
    4. Irani SR, et al

    . Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011;10:759–72 doi:10.1016/S1474-4422(11)70096-5 pmid:21777830

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Maeder-Ingvar M,
    3. Prior JO,
    4. Irani SR, et al

    . FDG PET hyperactivity in basal ganglia correlating with clinical course in anti-NDMA-R antibodies encephalitis. J Neurol Neurosurg Psychiatry 2011;82:235–36 doi:10.1136/jnnp.2009.198697 pmid:20667855

    FREE Full Text
27. 27.↵
    2. Probasco JC,
    3. Solnes L,
    4. Nalluri A, et al

    . Decreased occipital lobe metabolism by FDG PET/CT: an antip-NMDA receptor encephalitis biomarker. Neurol Neuroimmunol Neuroinflamm 2018;5:e413 doi:10.1212/NXI.0000000000000413 pmid:29159205

    CrossRefPubMed
28. 28.↵
    2. Dodich A,
    3. Cerami C,
    4. Iannaccone S, et al

    . Neuropsychological and FDG-PET profiles in VGKC autoimmune limbic encephalitis. Brain Cogn 2016;108:81–87 doi:10.1016/j.bandc.2016.07.010 pmid:27566001

    CrossRefPubMed
29. 29.↵
    2. Quartuccio N,
    3. Caobelli F,
    4. Evangelista L, et al

    ; Young AIMN Working Group. The role of FDG PET/CT in the evaluation of patients affected by limbic encephalitis: a systematic review of the literature. J Neuroimmunol 2015;284:44–48 doi:10.1016/j.jneuroim.2015.05.002 pmid:26025057

    CrossRefPubMed
30. 30.↵
    2. Mazzuca M,
    3. Jambaque I,
    4. Hertz-Pannier L, et al

    . 18F-FDG PET reveals frontotemporal dysfunction in children with fever-induced refractory epileptic encephalopathy. J Nucl Med 2011;52:40–47 doi:10.2967/jnumed.110.077214 pmid:21149491

    Abstract/FREE Full Text
31. 31.↵
    2. Nardetto L,
    3. Zoccarato M,
    4. Santelli L, et al

    . (18)F-FDG PET/MRI in cryptogenic new-onset refractory status epilepticus: a potential marker of disease location, activity and prognosis? J Neurol Sci 2017;381:100–02 doi:10.1016/j.jns.2017.08.021 pmid:28991656

    CrossRefPubMed
32. 32.↵
    2. Kantanen A,
    3. Reinikainen M,
    4. Parviainen I, et al

    . Long-term outcome of refractory status epilepticus in adults: a retrospective population-based study. Epilepsy Res 2017;133:13–21 doi:10.1016/j.eplepsyres.2017.03.009 pmid:28402834

    CrossRefPubMed
33. 33.↵
    2. Solnes LB,
    3. Jones KM,
    4. Rowe SP, et al

    . Diagnostic value of 18F-FDG PET/CT versus MRI in the setting of antibody-specific autoimmune encephalitis. J Nucl Med 2017;58:1307–13 doi:10.2967/jnumed.116.184333 pmid:28209905

    Abstract/FREE Full Text
34. 34.↵
    2. Newey C,
    3. Sarwal A,
    4. Hantus S

    . [18F]-fluoro-deoxy-glucose positron emission tomography scan should be obtained early in cases of autoimmune encephalitis. Autoimmune Dis 2016;2016:9450452 doi:10.1155/2016/9450452 pmid:27559482

    CrossRefPubMed